Form 4: AnaptysBio Chief Legal Officer Loumeau Exercises Options and Sells Shares

Eric Loumeau, Chief Legal Officer of AnaptysBio, Inc., executed stock options and sold shares to cover tax obligations, while also engaging in sales under a pre-arranged 10b5-1 trading plan.

Summary

• On September 14, 2024, Eric Loumeau, Chief Legal Officer of AnaptysBio, exercised restricted stock units (RSUs) to acquire 6,000 shares of common stock.
• On September 16, 2024, Loumeau sold 2,220 shares at $38.93 per share to cover tax withholding obligations related to the vesting of RSUs.
• Also on September 16, 2024, Loumeau exercised an option to purchase 5,000 shares at $14.02 per share.
• Further sales occurred on September 16, 2024, with 6,500 shares sold at $40.13 per share, and on September 17, 2024, with 3,780 shares sold at a weighted average price of $38.4103 per share.
• These sales on September 16 and 17 were executed under a pre-arranged 10b5-1 trading plan adopted on June 10, 2024.
• Following these transactions, Loumeau directly owns 7,020 shares of common stock and holds options to purchase 73,000 shares, in addition to other options to purchase up to 355,310 shares.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing primarily reflects routine transactions related to stock options and tax obligations. The use of a 10b5-1 plan suggests a planned approach to stock sales, reducing concerns about opportunistic trading.

Industry Context

Form 4 filings are standard disclosures required by the SEC when company insiders, like the Chief Legal Officer in this case, trade their company's stock. These filings are closely watched by investors for insights into management's perspective on the company's valuation and future prospects. The use of a 10b5-1 trading plan suggests a pre-arranged strategy to avoid accusations of insider trading.

Comparison to Industry Standards

• Comparing AnaptysBio's insider trading activity to companies like Amgen (AMGN) or Regeneron (REGN) shows similar patterns of executives using 10b5-1 plans for scheduled stock sales.
• The option exercise price of $14.02 is relatively low, indicating that the options were granted some time ago when the stock price was lower.
• The sales to cover tax obligations are a common practice among executives receiving equity compensation.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the increased supply of shares in the market.
• Employees holding stock options may be influenced by the executive's trading activity.

Key Dates